DV
Dividend Vision

AGMB Stock — AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV American Depositary Shares (AGMB)

Updated November 13, 2026.

AGMB is a stock. Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with a pipeline including oral and inhaled small molecule inhibitors for conditions such as Fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis, as well as a monoclonal antibody candidate. The company does not currently distribute to shareholders. This security appeals to investors with a high risk tolerance seeking exposure to early-stage drug development, as the company remains in clinical trials with no approved products generating revenue.

AGMB performance versus SPY

Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.

WindowTotal returnCAGR
1M-27.8%—
3M-54.4%—
6M-43.1%—
YTD-60.2%—
Since inception 2026-02-05 · 0.8 years-60.2%—

AGMB key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2026
Distribution frequency
None
Last close
$6.36 (as of 2026-11-13)
Market cap
$313,217,121
Average volume
192,639
Payout ratio
0.0%
EPS
-$2.08

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AGMB risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider AGMB — and who may not

It is a weaker fit for investors who need monthly cash flow (AGMB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AGMB

Tagged: Healthcare.

Frequently asked questions

Does AGMB pay monthly?

No. AGMB does not currently distribute.

When does AGMB pay a dividend?

AGMB does not currently distribute.

How has AGMB performed?

Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.